Camden National Corporation’s Novartis NVS Stock Holding History

Camden National Corporation’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$5.62M	Buy	+65,789	New	+$5.9M	1.12%	44

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Camden National Corporation's NVS Position: Q1 2021 in Review

Camden National Corporation opened a new position in Novartis (NVS) in Q1 2021: 65,789 shares worth $5.62M. The stake represents 1.12% of the portfolio and ranks #44 among its holdings.

1,136 funds tracked by Wall St. Rank hold NVS as of Q1 2021.

Camden National Corporation held 65,789 shares of Novartis worth $5.62M as of Q1 2021.
Novartis was a new Camden National Corporation position in Q1 2021.
Novartis made up 1.12% of Camden National Corporation's portfolio in Q1 2021, its #44 holding.
1,136 funds tracked by Wall St. Rank held Novartis as of Q1 2021.

Based on Camden National Corporation's 13F filing for Q1 2021, filed 12 May 2021.